LyGenesis
LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of Liver Regeneration Technology
LyGenesis, a Juvenescence partner, focused on organ regeneration, announced that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, and the Longevity Vision Fund.
October 20, 2019
Read MoreInsilico Medicine
Insilico Medicine secures $37M in Series B funding led by Qiming Venture Partners
Insilico Medicine, a next generation AI technology and Juvenescence partner, completes $37 million Series B funding that will be used to commercialize the validated generative chemistry and target identification technology.
September 9, 2019
Read MoreInsilico Medicine
Insilico Medicine Develops and Validates Powerful AI System To Transform Drug Discovery
Insilico Medicine has developed GENTRL, a new artificial intelligence system for drug discovery that dramatically accelerates the process from years to days.
September 1, 2019
Read MoreAgeX Therapeutics
AgeX Therapeutics publishes Theoretical Basis of Human Cell-Age Reversal in the Journal of Regenerative Medicine
AgeX Therapeutics, a Juvenescence biotechnology company focused on therapeutics for human aging and regeneration, announced today, the theoretical foundation of the Company’s induced Tissue Regeneration (iTRTM) technology.
August 27, 2019
Read MoreJuvenescence
Juvenescence closes $100 Million Series B Round
Juvenescence, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity.
August 18, 2019
Read MoreJuvenescence
Juvenescence appoints Colin Watts as CEO of Juvenescence Life
Juvenescence announces that Colin Watts has joined its Management Team as CEO of Juvenescence Life. Driving Human longevity and quality of life.
July 10, 2019
Read MoreJuvenescence
Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
May 27, 2019
Read MoreJuvenescence
Juvenescence Announces the Appointment of David Ellam as Chief Financial Officer
Juvenescence announces that David Ellam has joined its Executive Management Team as Chief Financial Officer.
April 23, 2019
Read MoreJuvenescence
Juvenescence Capitalizes BYOMass
Juvenescence is pleased to announce its latest equity investment in BYOMass, a Massachusetts-based company focused on central control of metabolism in the context of aging and age-related diseases.
March 26, 2019
Read MoreBHB Therapeutics
Juvenescence and the Buck Institute launch BHB Therapeutics
Juvenescence and the Buck Institute for Research on Aging announce a new collaboration with the formation of BHB Therapeutics a joint venture.
February 3, 2019
Read MoreJuvenescence
Juvenescence closes First $46M Tranche of $100M Series B
Juvenescence is pleased to announce the close of the first tranche of its Series B financing, in the amount of $46 million.
January 15, 2019
Read MoreNapa Therapeutics
Juvenescence, The Buck Institute, and Insilico Medicine establish Napa Therapeutics
.Juvenescence, The Buck Institute for Research on Aging, and Insilico Medicine announced today that they have formed Napa Therapeutics, to develop drugs against a novel aging-related target.
August 13, 2018
Read MoreJuvenescence
Juvenescence Series A, Nets $50 Million
Juvenescence has successfully raised $50 million in its Series A financing. The Series A financing was oversubscribed with participation from founders, insiders, institutional investors and family offices.
June 10, 2018
Read MoreJuvenescence
Karim Hakimzadeh Appointed to Board of Directors
Juvenescence announced the appointment of Karim Hakimzadeh to its Board of Directors. The appointment increases the size of the Board of Directors to five members.
February 13, 2018
Read MoreJuvenescence
Juvenescence Closes Seed Round of USD $12.3 Million with Participation from Seasoned Biotech Investors
Juvenescence announced that it has closed its seed funding round, raising USD $12.3 million. The Seed Round was included undisclosed sums from a range of seasoned international angel investors and institutions.
January 7, 2018
Read More
